Result for
Tag: variants
February 18, 2021
Circulating SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity
[Pre-print, not peer reviewed] Analysis of neutralizing activity of sera from individuals vaccinated with either 1 or 2 doses of the Moderna or Pfizer vaccines (n=48) against SARS-CoV-2 pseudoviruses bearing spike proteins with the partial or full set of mutations from the B.1.351 variant show up to a 97-fold decrease in neutralization compared to wild-type. …
February 17, 2021
CD8+ T Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes from Multiple Prominent SARS-CoV-2 Circulating Variants
[Pre-print, not peer-reviewed] A study assessing whether CD8+ T-cells from COVID-19 convalescent individuals (n=30) can recognize SARS-CoV-2 variant epitopes showed that only one of the three most prominent variants (the B.1.351 variant, first described in South Africa) had a mutation that overlapped with a low-prevalence CD8+ epitope. Out of 45 mutations assessed, this mutation was…
SARS-CoV-2 Variants Show Resistance to Neutralization by Many Monoclonal and Serum-Derived Polyclonal Antibodies
[Pre-print, not peer-reviewed] Most convalescent sera from people who had recovered from COVID-19 and virtually all Pfizer-BioNTech mRNA vaccine-induced immune sera were shown to have diminished neutralizing activity against engineered SARS-CoV-2 strains including a chimeric strain combining a strain identified in Washington state with a B.1.351 spike gene (Wash SA-B.1.351 strain), or recombinant viruses containing…
501Y.V2 and 501Y.V3 Variants of SARS-CoV-2 Lose Binding to Bamlanivimab in Vitro
[Pre-print, not peer-reviewed] Three mutations found in the B.1.1.351 variant (first identified in South Africa) and the P1 variant (first identified in Brazil) completely abolished the interaction of monoclonal antibody treatment bamlanivimab with the receptor binding domain (RBD) of the virus. Additionally, the K417N, E484K, and N501Y mutations found in the variants had higher binding…
Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
The SARS-CoV-2 variant strain B.1.351 (first described in South Africa) was detected in Zambia in specimens collected from December 16–23, 2020. Among 23 specimens collected during this time, 22 (96%) were the B.1.351 variant, and among those 21 (95%) contained all nine B.1.351 lineage-defining mutations. Specimens with the B.1.351 variant were obtained from people across…
First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota — December 2020–January 2021
On January 9, 2021, the Minnesota Department of Health announced the identification of the B.1.1.7 SARS-CoV-2 variant (first described in the UK) in specimens from five people, and on January 25, this variant was found in samples from three additional people. The samples were collected between December 18, 2020 and January 11, 2021 from residents…
February 16, 2021
Sensitivity of Infectious SARS-CoV-2 B.1.1.7 and B.1.351 Variants to Neutralizing Antibodies
[Pre-print, not peer reviewed] The SARS-CoV-2 B.1.1.7 variant (first described in the UK) was experimentally shown to have similar sensitivity to the neutralizing activity of convalescent sera (n=83) collected up to 9 months post symptom onset compared to the wild-type virus. In contrast, neutralizing titers had a mean 6-fold reduction against the B.1.351 variant (first…
Analysis of SARS-CoV-2 Mutations in the United States Suggests Presence of Four Substrains and Novel Variants
Whole genome sequencing of 12,754 SARS-CoV-2 sequences from the US suggests the presence of 4 substrains and 11 most frequent mutations as of September 11, 2020. The 2 most common mutations are also the top 2 in the world (D614G mutation in the spike protein and the P323L mutation), both of which were detected in…
S-Variant SARS-CoV-2 Lineage B1.1.7 Is Associated with Significantly Higher Viral Loads in Samples Tested by ThermoFisher TaqPath RT-QPCR
Individuals infected with the SARS-CoV-2 B.1.1.7 variant (first described in the UK) may have considerably higher viral loads, which could potentially explain the higher transmissibility of this variant. Analysis of 641 SARS-CoV-2 PCR positive samples in the UK from October to November 2020 showed that samples suspected to have the B.1.1.7 variant, identified by a…
February 11, 2021
Effect of the New SARS-CoV-2 Variant B.1.1.7 on Children and Young People
The clinical course of SARS-CoV-2 infection among children may be similar when infection occurs with the B.1.1.7 variant versus the original strain, according to an analysis of two cohorts of children admitted to King’s College Hospital for COVID-19. The B.1.1.7. variant accounted for ~70% of SARS-CoV-2 infections in London by January 2021 and the two…
Previous page Next page